Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0851341 (
infestation
)
10,121
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This article discusses two common causes of
lung disease
in the dog and cat: tracheobronchitis and bacterial pneumonia. Information about parasitic
infestation
of the trachea, bronchi, and lung parenchyma is summarized. Data are also presented regarding the sensitivities of bacterial infections of the respiratory tract to antibiotics.
...
PMID:Lung infections and infestations. Therapeutic considerations. 164 15
Strongyloidiasis is a tenacious soil-transmitted nematode
infestation
endemic in the south-eastern United States. Thirty-three cases were diagnosed in a series of 1,290 stool examinations in 971 patients at Veterans Administration Medical Center, Mountain Home, Tennessee. Most patients had a concurrent major illness, such as chronic
lung disease
, serious bacterial infection, or cancer. A minority presented with gastrointestinal symptoms alone. Skin rash was uncommon. Eosinophilia, IgE elevation, and skin anergy were common. Atypical presentations included severe proctitis, colitis, and exacerbation of inflammatory bowel disease. In a patient with the hyperinfection syndrome, the diagnosis was made only at autopsy. Since strongyloidiasis seems to present like an opportunistic illness, all physicians, not just those in endemic areas, should consider its presence in the appropriate setting.
...
PMID:Strongyloidiasis. When to suspect the wily nematode. 660 65
Aspergillus is a ubiquitous dimorphic fungus that causes a variety of human diseases ranging in severity from trivial to life-threatening, depending on the host response. An intact host defence is important to prevent disease, but individuals with pre-existing structural
lung disease
, atopy, occupational exposure or impaired immunity are susceptible. Three distinctive patterns of aspergillus-related
lung disease
are recognized: saprophytic
infestation
of airways, cavities and necrotic tissue; allergic disease including extrinsic allergic alveolitis, asthma, allergic bronchopulmonary aspergillosis, bronchocentric granulomatosis and chronic eosinophilic pneumonia; and airway and tissue invasive disease -- pseudomembranous tracheobronchitis, acute bronchopneumonia, angioinvasive aspergillosis, chronic necrotizing aspergillosis and invasive pleural disease. A broad knowledge of these clinical presentations and a high index of suspicion are required to ensure timely diagnosis and treatment of the potentially lethal manifestations of aspergillus-related pulmonary disease. In the present report, the clinical, radiographic and pathological aspects of the various aspergillus-related lung diseases are briefly reviewed.
...
PMID:Aspergillus-related lung disease. 1630 29
Airway infections are considered as one of the vital factors driving the pathophysiology of chronic
lung disease
with significant influences on disease trajectory. Opportunistic lung microbes in diseased conditions induce excessive exacerbations and contribute to airflow limitation. Though there has been considerable amount of information that ascertains their links with airway inflammation, the intricate interaction in clinical conditions are poorly understood and requires further deciphering. Current therapeutic interventions for such pathologies are few and lack the ability to modulate underlying dysfunctional immunity as well as suppress the excessive infectious conditions. Thus, in this Commentary we provide a focused outlook on the mechanisms involved in microbial
infestation
in lung diseases and provides important information on new therapeutic interventions including the potential role of Resolvins and their derivatives as alternative therapeutic agents in combating such multifaceted pathological mechanisms.
...
PMID:Understanding novel mechanisms of microbial pathogenesis in chronic lung disease: implications for new therapeutic targets. 2943 18